Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 3776 - 3792 of 3792 in total
Experimental
Matched Name: … yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
Matched Iupac: … ethyl]carbamoyl}-2-{4-[difluoro(phosphono)methyl]phenyl}ethyl]carbamoyl}-4-(phenylformamido)butanoic acid
Experimental
Matched Name: … CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID
Experimental
Matched Name: … METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID
Experimental
Matched Name: … CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID
Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational
Matched Synonyms: … ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH …
Matched Description: … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP ... It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Proteins ... Blood Proteins ... Recombinant Proteins ... Recombinant Fusion Proteins
Experimental
Matched Name: … hydroxy)methoxy]-2,3-dihydro-1H-inden-1-yl}-2-benzyl-3-oxo-2-pyrrolidinyl]-3-hydroxy-1-phenyl-2-butanyl}carbamate
Matched Iupac: … hydroxy)methoxy]-2,3-dihydro-1H-inden-1-yl]-2-benzyl-3-oxopyrrolidin-2-yl]-3-hydroxy-1-phenylbutan-2-yl}carbamate
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin...
Approved
Investigational
Matched Synonyms: … DILACTONE ACTINOMYCIN D ACID
Matched Description: … It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than ... As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances ... Nucleic Acid Synthesis Inhibitors ... Protein Synthesis Inhibitors …
Experimental
Matched Name: … (6Z)-6-{[(1Z)-1-{[(1R)-1-Carboxy-2-methyl-2-propen-1-yl]imino}-1-hydroxy-3-sulfanyl-2-propanyl]imino} …
Matched Iupac: … carboxy-2-methylprop-2-en-1-yl]-C-hydroxycarbonimidoyl}-2-sulfanylethyl)-C-hydroxycarbonimidoyl]pentanoic acid
Experimental
Matched Name: … phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
Matched Iupac: … phosphono)methyl]phenyl}ethyl]carbamoyl}-3-(2-{4-[difluoro(phosphono)methyl]phenyl}acetamido)propanoic acid
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate...
Approved
Investigational
Matched Synonyms: … tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen
Matched Description: … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations ... of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and ... Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Experimental
Matched Name: … methyl]tetrahydro-2-furanyl}amino)-2-oxoethyl]amino}-2-hydroxy-2-propanyl]benzoyl}ami no)pentanedioic acid
Matched Iupac: … phosphonooxy)methyl]oxolan-2-yl]carbamoyl}methyl)amino]-2-hydroxypropan-2-yl]phenyl}formamido)pentanedioic acid
Investigational
Matched Synonyms: … 2-propen-1-one, 1-((3S)-4-((7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl)-6-chloro-8-fluoro …
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone...
Approved
Matched Description: … RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and ... an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and ... Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and
Matched Mixtures name: … Zinda-candesartan/hydrochlorothiazide ... Zinda-candesartan/hydrochlorothiazide ... Candesartan Cilexetil and Hydrochlorothiazide …
Matched Categories: … Angiotensin II Antagonists and Diuretics …
Matched Products: … Zinda-candesartan …
Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3).
Investigational
Matched Synonyms: … ALL-P-AMBO-5'-O-(((6-(5-((TRIS(3-(6-(2-ACETAMIDO-2-DEOXY-.BETA. …
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors...
Approved
Investigational
Matched Description: … that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and ... [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. ... In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and
Matched Categories: … 5-alpha Reductase Inhibitors ... Genito Urinary System and Sex Hormones ... ambrisentan and tadalafil ... tamsulosin and tadalafil ... finasteride and tadalafil …
Matched Products: … TADALAFIL BETA PAH 20MG …
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 . It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for...
Approved
Matched Description: … It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be ... Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue ... used instead of other macrolides for some sexually transmitted and enteric infections. …
Matched Categories: … cefixime and azithromycin ... Macrolides, Lincosamides and Streptogramins ... azithromycin, fluconazole and secnidazole ... Medications that reduce magnesium levels …
Matched Products: … PROSFIN 500 MG …
Displaying drugs 3776 - 3792 of 3792 in total